Objective: Endovascular abdominal aortic aneurysm (AAA) grafts are subject
to subsequent failure of endograft limbs. We sought to determine what devic
e-related factors could be identified that might contribute to limb failure
.
Methods: We reviewed the records of patients who had undergone endovascular
AAA repair and femorofemoral bypass grafting at a single institution.
Results: Endovascular AAA repair was performed in 173 patients. There were
137 bifurcated endografts and 36 aortomonoiliac grafts combined with femoro
femoral bypass grafts, yielding a total population of 310 aortic graft limb
s and 36 femorofemoral grafts. Thirty-nine additional patients underwent fe
morofemoral bypass grafting for occlusive disease. The cumulative primary p
atency of all endografts performed for AAA was 92% at 21 months. Secondary
patency was achieved for all failed endograft limbs. There were 24 aortic g
raft limb "failures" that required intervention: seven limbs underwent thro
mbosis requiring revision; kinked limbs requiring stenting either at the ti
me of graft placement (17) or subsequently (7) were identified. Fully suppo
rted endograft limbs had better primary patency (97% at 18 months) than uns
upported limbs (69% at 18 months, P <.001). The aortomonoiliac grafts with
femorofemoral bypass grafts tended to have better patency (97% at 18 months
) than bifurcated endografts (90% at 18 months), but this did not reach sta
tistical significance (P = .28, not significant). Femorofemoral grafts perf
ormed for occlusive disease were found to have somewhat lower patency than
those performed for AAA (83% vs 92% at 18 months of follow-up, P = .37, not
significant).
Conclusions: fully supported AAA endografts provide superior endograft limb
patency compared with unsupported designs. Consideration should be given t
o routine stenting of all unsupported endograft limbs. Aortomonoiliac graft
s and bifurcated grafts provide similar results for endograft limb patency.
Femorofemoral bypass grafts performed in conjunction with aortomonoiliac g
rafts for ABA disease provide excellent short-term patency.